In the BioHarmony Drug Report Database

"Preview" Icon

Mepolizumab

Nucala (mepolizumab) is an antibody pharmaceutical. Mepolizumab was first approved as Nucala on 2015-11-04. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.

 

Trade Name

 

Nucala
 

Common Name

 

mepolizumab
 

ChEMBL ID

 

CHEMBL2108429
 

Indication

 

asthma
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating

Image (chem structure or protein)

Mepolizumab structure rendering